GCT - NK cell therapy

Drug Profile

GCT - NK cell therapy

Alternative Names: GCT NK cells; Natural killer cells - Glycostem; NK cells - Glycostem; UCB-NK cell

Latest Information Update: 22 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glycostem Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Dec 2015 Safety and efficacy data from a phase I trial in Acute myeloid leukaemia presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top